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Thyroid disorders such as goiters represent important diseases, especially in iodine-deficient areas. Sibling studies have demonstrated
that genetic factors substantially contribute to the interindividual variation of thyroid volume. We performed a genome-wide associa-
tion study of this phenotype by analyzing a discovery cohort consisting of 3620 participants of the Study of Health in Pomerania (SHIP).
Four genetic loci were associated with thyroid volume on a genome-wide level of significance. Of these, two independent loci are located
upstream of and within CAPZB, which encodes the b subunit of the barbed-end F-actin binding protein that modulates actin polymer-
ization, a process crucial in the colloid engulfment during thyroglobulinmobilization in the thyroid. The third locusmarks FGF7, which
encodes fibroblast growth factor 7. Members of this protein family have been discussed as putative signal molecules involved in the
regulation of thyroid development. The fourth locus represents a ‘‘gene desert’’ on chromosome 16q23, located directly downstream
of the predicted coding sequence LOC440389, which, however, had already been removed from the NCBI database as a result of the
standard genome annotation processing at the time that this study was initiated. Experimental proof of the formerly predicted mature
mRNA, however, demonstrates that LOC440389 indeed represents a real gene. All four associations were replicated in an independent
sample of 1290 participants of the KORA study. These results increase the knowledge about genetic factors and physiological mecha-
nisms influencing thyroid volume.From the clinical and the public-health point of view,
thyroid disorders such as nontoxic and toxic goiter are rele-
vant diseases in previously and currently iodine-deficient
areas. Whereas goiters are highly prevalent in iodine-defi-
cient regions, it is less commonly present in iodine-replete
areas.1,2 The effect of iodine deficiency on goiter risk is
pronounced by cigarette smoking, whereas this association
is not present in regions with optimal iodine supply.3–5
Additional environmental factors include gender, age, and
body mass index.3,5 There is no doubt that genetic factors
also play a substantial role in the etiology of simple
goiter.6,7 Sibling studies fromDenmark, a regionwith previ-
ously mild to moderate iodine deficiency, demonstrated
a higher intraclass correlation for thyroid volume inmono-
zygotic twins as compared to dizygotic twins, suggesting
that genetic factors account for approximately 61%–78%
of the interindividual variation of the thyroid volume.7
Whereas genetic loci associated with clinically overt euthy-
roid multinodular goiter were already mapped in linkage
analyses, genome-wide association studies (GWAS) investi-
gating genetic factors with regard to thyroid enlargement
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iodine-deficient area with moderate iodine deficiency in
the northeast and moderate to severe iodine deficiency in
the south.8,9 A voluntary iodine fortification program was
introduced in Germany during the 1980s. In December
1993, improved legislations concerning the iodization of
table salt became effective, which contributed to an
increase in the use of iodized salt for food production, re-
sulting in a stable iodine supply during the past 15 years.
In the discovery-stage GWAS, 3620 individuals, aged 20–
79 years, from the baseline examinations of the Study of
Health in Pomerania (SHIP-010) inWest Pomerania (north-
east Germany) were analyzed for associations of SNPs with
the phenotypes ‘‘thyroid volume’’ and ‘‘goiter.’’ The lead
SNPs of the four identified loci that exhibited genome-
wide significant associations for ‘‘thyroid volume’’ and
the corresponding SNPs of these loci that showed the
strongest associations to ‘‘goiter’’ were replicated in 1290
individuals, aged 30–79, years from the Kooperative
Gesundheitsforschung in der Region Augsburg (KORA F4,
southern Germany11). Finally, we performed a combined
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Table 1. Cohort Characteristics
Study of Health in
Pomerania (SHIP)
Cooperative Health Research in the
Region of Augsburg, Survey 4 (KORA F4)
Study design population-based population-based
Sample size 3620 1290
Age in years (range) 49 (20–81) 60 (32–79)
Females (%) 1716 (47.4) 541 (41.9)
Current smokers (%) 1143 (31.57) 210 (16.29)
BSA in m2 (SD) 1.89 (0.21) 1.90 (0.21)
Thyroid volume in ml (SD) 21.28 (11.43) 21.55 (10.9)
Presence of goiter (%) 1325 (36.6) 467 (36.2)
Thyroid measurement Ultrasound VST-Gateway 5 MHz
linear array transducer (Diasonics)
SONOLINE G50 5 MHz linear array
transducer (Siemens Medical)
Thyroid volume calculation length 3 width 3 depth 3 0.479 [ml] for each lobe34
Thyroid
measurement QC
Intra- and interobserver reliabilities within and between both studies were assessed before the start of each
study and afterwards annually during the studies; analyses were performed according to Bland and Altman.35 All
measurements of the thyroid volume for within and between study comparisons showed Spearman correlation
coefficients of > 0.85 and mean differences (þ 2 SD) of the mean bias of < 5% (<25%).
Sample exclusions by
phenotype
Individuals taking thyroid medication or reporting thyroid disorders, women pregnant at the time of thyroid
measurementAll participants were of European ancestry. Approval was
obtained by local ethic committees, and informed consent
was given by all participants. Goiter was defined as
a thyroid volume of > 18 ml in women and of > 25 ml
in men.12 Subjects with known thyroid disease or those
with previous or current antithyroid treatment were
excluded from the analyses, because potentially relevant
treatment effects on thyroid volume cannot be quanti-
fied.13,14 The detailed characteristics of the study popula-
tions, exclusion criteria, and quality control procedures
are described in Table 1. Genotyping information and
GWAS details are specified in Table S1 (available online).
All SNPs with a minor allele frequency < 0.01 were
excluded. Since all X-linked SNPs were excluded from
imputation,15 27.399 directly genotyped SNPs of chromo-
some X and 46 directly genotyped SNPs frommtDNA (SNP
call ratesR 80%, pHWE > 0.001, MAF > 1%) were tested in
an additional analysis in the discovery stage. None of these
SNPs showed genome-wide significant associations with
‘‘thyroid volume’’ or ‘‘goiter.’’ Associations were tested
with the use of a linear additive model on natural log-
transformed thyroid volume (ml) for the ‘‘thyroid volume’’
phenotype and a logistic regression analysis for the
‘‘goiter’’ phenotype, respectively. Adjustment for age,
gender, current smoking state (yes or no), and body surface
area (BSA) was performed for all analyses. All p values of
the discovery GWAS and the results of the meta-analysis
were corrected for genomic control. Only SNPs, for which
association data from both studies were available, were
included in the meta-analysis. Associations were consid-
ered to have genome-wide significance below a p value
of 5 3 108.16 Genomic control was applied both for theThe Ameindividual cohorts and for the combined results. The
estimated genomic control was low for ‘‘thyroid volume’’
and ‘‘goiter’’ for both the individual-cohort analysis
(Table S1) and the combined analyses (lGC ¼ 1.058 and
lGC ¼ 1.021, respectively), suggesting little residual con-
founding due to population stratification (Figure S1). All
SNPs found to be associated with one of the two pheno-
types of interest in the discovery GWAS, the replication
stage, or the combined analysis were in Hardy-Weinberg
equilibrium (p > 0.001) in both studies. To identify inde-
pendently associated loci, SNPs were clumped with the
use of the PLINK17 clumping algorithm of (r2 > 0.1, 1 Mb
distance) based on genotype data of 4105 SHIP partici-
pants. To validate the independence of the four loci for
‘‘thyroid volume’’ in the discovery stage, the lead SNPs of
these loci were analyzed together in a multivariate linear
regression model, in which the associations remained
significant and mostly unchanged, indicating statistical
independence of the four SNPs from each other (Table 2).
The discovery analysis identified four loci associated
with ‘‘thyroid volume’’ at a genome-wide significance
level. Two of these loci were also significantly associated
with ‘‘goiter,’’ whereas the other two missed genome-
wide significance in the discovery stage (see Table 3). The
strongest associations were found for the CAPZB region
on chromosome 1p36. Within this region, two indepen-
dent loci were significantly associated with both ‘‘thyroid
volume’’ and ‘‘goiter’’: at the locus upstream of CAPZB,
rs12138950 represented the lead SNP for both phenotypes.
Within CAPZB, rs12091047 represented the lead SNP for
‘‘thyroid volume,’’ whereas rs12033437 was the lead SNP
for ‘‘goiter.’’ For the third locus at 15q21, the lead SNPsrican Journal of Human Genetics 88, 664–673, May 13, 2011 665
Table 2. Results from the Analysis of Independence and the Explained Variance of the Lead SNPs of the Four Loci Associated with the
‘‘Thyroid Volume’’ Phenotype in the Discovery-Stage GWAS
Discovery-Stage GWAS SHIP KORA
Locus Lead SNP p Value Effect SE Variance Explained p Value Effect SE Variance Explained
1 rs12138950 4.700 3 1013 0.093 0.013 3.33% 3.988 3 106 0.103 0.022 3.18%
2 rs1354920 2.530 3 109 0.060 0.010 6.619 3 103 0.048 0.018
3 rs17767491 7.390 3 1011 0.063 0.010 4.437 3 104 0.060 0.017
4 rs12091047 3.250 3 108 0.054 0.010 2.775 3 104 0.059 0.016
The values were calculated by analyzing all SNPs adjusted for sex, age, smoking status, and body surface area in a linear regression model. Compared to the results
in Table 3, the p values have changed only marginally, indicating statistical independence of the four SNPs from each other.for both phenotypes (rs1354920 for ‘‘thyroid volume’’ and
rs1023683 for ‘‘goiter’’) were located within C15orf33 in
close vicinity of FGF7.
The fourth locus at 16q23 was located within a 110 kb
distance of the next annotated gene (MAF) and was not
in linkage disequilibrium with it, and it was therefore
initially designated as a ‘‘gene desert’’ (see Figure 2). The
lead SNPs of this locus were rs17767491 for ‘‘thyroid
volume’’ and rs3813579 for ‘‘goiter.’’
All four loci were positively replicated in the second
stage in KORA-F4 (Table 3). Finally, a GWAS using the
SNP data from both studies was performed, including
a study population of n ¼ 4910. This combined analysis
did not reveal additional, yet-unidentified genome-wide
significant associations with the two phenotypes.
However, all four loci detected in the primary stages were
confirmed and exhibited even stronger associations than
those in the discovery analysis (Table 4, Figure 1). In
several cases, the combined analysis yielded lead SNPs
that were different from those of the discovery GWAS
but were consistently found to be in distinct linkage
disequilibrium with the former. The lead SNPs of the loci
at 16q23 (‘‘gene desert’’) and at 1p36 within CAPZB nowTable 3. SNPs within the Four Loci that Show the Strongest Associati
Discovery-Stage GWAS
Locus Chr. Position Lead SNP SHIP pGC SHIP p KORA
Thyroid Volume
1 1 19711702 rs12138950 9.340 3 1014 2.333 3 1006
2 15 47612815 rs1354920 1.130 3 1008 7.656 3 1003
3 16 78302988 rs17767491 1.240 3 1010 8.571 3 1004
4 1 19644512 rs12091047 2.530 3 1009 8.400 3 1005
Goiter
1 1 19711702 rs12138950 6.666 3 1011 7.111 3 1005
2 15 47494739 rs1023683 1.651 3 1008 9.199 3 1007
3 16 78306777 rs3813579 8.138 3 1008 8.457 3 1004
4 1 19622481 rs12033437 1.499 3 1007 2.844 3 1005
Allele 1, effect allele; Allele 2, other allele; Freq1, frequency of allele 1; ImpQual,
p value of the association after genomic control has been applied; R2, linkage diseq
ysis GWAS of the same locus.
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‘‘goiter’’ (Table 4, Figure 1). We tested for interactions
between the lead SNPs of the four ‘‘thyroid volume’’ loci
in SHIP, but we did not observe any significant results
(p > 0.05). For each individual, the number of alleles of
all four loci increasing the thyroid volume was counted,
and the mean increment of the log thyroid volume per
allele was estimated. The results are shown in Table 5.
Sensitivity analyses included anti-TPO antibody status
and serum concentrations of TSH, free T3, and free T4 as
potential confounders without substantially affecting the
key results (Table S2).
The twoCAPZB loci associated with both phenotypes are
clearly independent from each other, as their lead SNPs are
not in significant linkage disequilibrium (r2 ¼ 0.004).
Furthermore, the effects of their minor alleles on ‘‘thyroid
volume’’ and ‘‘goiter’’ are inverse. CAPZB encodes the two
b subunit isoforms of the capping protein (CP), also known
as the barbed-end actin binding protein. CP represents
a heterodimeric protein composed of a and b subunits.
The a1 and a2 subunit isoforms of CP are encoded
by CAPZA1 and CAPZA2, respectively. Both b subunit
isoforms encoded by CAPZB are specified by differentialon with the ‘‘Thyroid Volume’’ and ‘‘Goiter’’ Phenotypes in the
pGC META Allele 1 Allele 2 Freq1 ImpQual R
2
2.876 3 1018 C A 0.154 0.989 same SNP
4.923 3 1010 T C 0.302 0.970 0.60
8.071 3 1013 G A 0.322 1.000 1.00
1.777 3 1012 T C 0.343 0.993 0.97
3.641 3 1014 C A 0.154 0.989 0.60
3.864 3 1013 T A 0.758 0.991 0.83
3.868 3 1010 G A 0.482 0.997 same SNP
4.055 3 1011 T C 0.334 1.000 0.97
imputation quality measurement (observed by expected variance ratio); pGC,
uilibrium value for the respective lead SNP with the lead SNP of the meta-anal-
2011
Table 4. SNPs within the Four Loci with Strongest Association with the ‘‘Thyroid Volume’’ and ‘‘Goiter’’ Phenotypes in the Combined
Meta-Analysis
Locus Chr. Position Lead SNP pGC Effect SE Allele 1 Allele 2 Freq1
Thyroid Volume
1 1 19711702 rs12138950 2.876 3 1018 0.102 0.012 A C 0.847
2 15 47522589 rs4338740 1.441 3 1012 0.067 0.009 T C 0.738
3 16 78302049 rs17767419 9.418 3 1015 0.068 0.009 T C 0.321
4 1 19638105 rs12045440 3.237 3 1014 0.067 0.009 T G 0.664
Goiter
1 1 19715941 rs10917468 1.114 3 1014 0.66 0.59–0.73 T C 0.783
2 15 47522589 rs4338740 2.843 3 1013 0.69 0.63–0.76 T C 0.739
3 16 78306777 rs3813579 3.868 3 1010 1.32 1.21–1.44 A G 0.518
4 1 19638105 rs12045440 1.649 3 1011 1.38 1.26–1.51 T G 0.664
Chr, chromosome; Allele 1, effect allele; Allele 2, other allele; Freq1, frequency of allele 1; pGC, p value of the association after genomic control has been applied.pre-mRNA splicing.18 In spite of pronounced amino acid
sequence differences between the carboxy termini of b1
and b2, both subunit isoforms exhibit comparable actin-
binding activities.19 Therefore, the b subunit carboxy
termini, besides binding actin, may interact with different
target proteins that might regulate their activity.20 This is
substantiated by the fact that the two b isoforms exhibit
tissue-specific expression: whereas b2 represents the pre-
vailing isoform of nonmuscle tissues, b1 predominates in
muscle tissues.18
In the thyroid, TSH-induced engulfment of the colloid by
extension of microvilli and filopodia protruding in the
thyroid follicular lumen from the surface of thyrocytes
represents a key step for thyroglobulin mobilization. The
resulting endocytotic vesicles fuse with lysosomes, and
proteolysis of thyroglobulin releases mono-, di-, tri-, and
tetraiodthyronine (T1, T2, T3, and T4, respectively). Poly-
merization of actin is crucial in the formation and exten-
sion of microvilli and filopodia. CP represents a major
antagonist of filopodia formation.21,22 The elongation
status of the barbed end of actin filaments can be regarded
as the net result of the interplay between capping and anti-
capping activities, with CP as the major barbed-end termi-
nator.21 On the other hand, the barbed-end actin-binding
activity of CP is modulated by additional regulatory
proteins that are, in turn, able to bind to and sequester
the former. Known examples of this are the CARMIL and
V-1/myotrophin proteins that can bind to CP and inhibit
its binding to the barbed end of the actin filament, i.e., its
capping function.22 Interestingly, the CP-binding activity
of V-1/myotrophin is regulated by cAMP, the most impor-
tant secondmessenger involved in the TSH signal transduc-
tion.23 The lead SNP showing the strongest association
with both phenotypes in our combined analysis,
rs12138950, is located in the upstream region of CAPZB
(Figure 2). Therefore, it can be speculated that the causative
sequence variant underlying the association of this locus
with ‘‘thyroid volume’’ and ‘‘goiter’’ might influence theThe Ameactivity of the CAPZB promoter, thereby modulating the
expression level of the gene. As theminor allele of this locus
is associated with increased thyroid volume and risk of
goiter, the postulated causative polymorphism most prob-
ably represents a promoter-up variant, causing an increased
b2 subunit amount in the thyrocyte. Given that both
subunits are unstable in the absence of the other subunit
but stabilized in its presence,24 the total amount of the
active CP heterodimer might also be increased. According
to this model, alleviated reception of the incoming TSH/
cAMP signal as a result of attenuated uncapping activity
would result in reduced thyroglobulin engulfment by filo-
podia, decreased T3/T4 release, and, in turn, compensatory
thyroid hyperplasia and increased thyroid volume.
In the secondCAPZB locus, the lead SNP for both pheno-
types in the combined analysis, rs12045440, is located
within the first of the nine introns of CAPZB (Figure 2).
Because this locus is marked by a genic lead SNP, one
may hypothesize that at least one, yet-unidentified,
sequence polymorphism in linkage disequilibrium with
the associated SNPs represents a nonsynonymous SNP
causing an amino acid exchange in the encoded b2
subunit. Because the minor allele of this locus is associated
with decreased thyroid volumes, the b2 variant specified
by this allele might exhibit a more sensitive response to
the TSH/cAMP signal, resulting in enhanced uncapping
compared to the major allele. This could be caused by an
improved interaction of CP with at least one protein that
negatively regulates the capping activity, such as cAMP-
activated V-1/myotrophin. Accordingly, improved recep-
tion of the incoming TSH/cAMP signal would result in
accelerated thyroglobulin engulfment by filopodia,
increased T3/T4 release, and, in turn, compensatory
thyroid hypoplasia and decreased thyroid volume.
Recently, Panicker et al. described an association
between the SNP rs10917469 and TSH serum concentra-
tion.25 This SNP is located upstream of CAPZB and in
strong linkage disequilibrium with the lead SNPs of ourrican Journal of Human Genetics 88, 664–673, May 13, 2011 667
Figure 1. Manhattan Plots Showing the Significance of Association of All SNPs in the Meta-Analysis with the Phenotypes
(A and B) ‘‘Thyroid volume’’ (A) and ‘‘goiter’’ (B). SNPs are plotted on the x axis according to their position on each chromosome against
association with the respective phenotype on the y axis (shown as log10 p value). SNPs were filtered by minor allele frequency of 1%.
The black horizontal line indicates the threshold for genome-wide significance.
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Table 5. Mean of Log Thyroid Volumes of Individuals Carrying the Specified Number of ‘‘Thyroid Volume’’-Increasing Alleles of the Four
Lead SNPs in the Combined Analysis
SHIP KORA
No. of Risk Alleles Mean 95% CI Freq. Freq. % Mean 95% CI Freq. Freq. %
0 2.77 [2.68,2.85] 76 2.10 2.75 [2.60,2.89] 29 2.26
1 2.84 [2.8,2.87] 459 12.69 2.81 [2.75,2.87] 160 12.45
2 2.90 [2.87,2.92] 962 26.59 2.91 [2.87,2.95] 347 27.00
3 2.97 [2.94,2.99] 1077 29.77 2.95 [2.91,2.99] 412 32.06
4 3.01 [2.99,3.04] 726 20.07 3.06 [3.01,3.11] 249 19.38
5 3.10 [3.05,3.15] 253 6.99 3.25 [3.17,3.34] 74 5.76
6 3.16 [3.06,3.26] 61 1.69 3.26 [3.04,3.46] 13 1.01
7 3.32 [2.94,3.7] 4 0.11 3.46 [2.70,4.23] 1 0.08
Total 3618 100.00 1285 100.00
The number of risk alleles ranges from 0 to 7. There were no individuals homozygous for the thyroid increasing allele at all four loci. Freq denotes frequency; the
number of individuals carrying the corresponding number of risk alleles. Freq %, percentage of individuals carrying the corresponding number of risk alleles.combined analysis for ‘‘thyroid volume’’ and ‘‘goiter’’
(rs12138950: r2 ¼ 1.00; rs10917468: r2 ¼ 0.60, respec-
tively). The minor G allele of rs10917469 (MAF ¼ 0.16) is
associated with lower TSH serum concentrations than
the major A allele. Because the minor alleles of
rs12138950 (MAF ¼ 0.15) and rs10917468 (MAF ¼ 0.22)
are in linkage disequilibrium with the minor allele of
rs10917469, they obviously belong to one common haplo-
type that is associated not only with TSH serum concentra-
tions, but also with thyroid volume and goiter.
The results of Panicker et al.25 can be integrated in the
model described above: the increased activity of theCAPZB
promoter mediated by the associated haplotype will cause
attenuated uncapping activity in response to the incoming
TSH/cAMP signal in thyrocytes and, finally, compensation
by increased thyroid volumes. After thyroid growth finally
ceases, this compensatory hyperplasia results in the
production of amounts of T3 and T4 that are even above
the physiological threshold values. As the result of nega-
tive feedback regulation, the increased amounts of T3
and T4 would trigger reduced production and secretion
of TSH until the concentrations of the thyroid hormones
are again in the physiological range. In the new equilib-
rium, an increased thyroid volume would then be associ-
ated with decreased TSH serum concentrations, whereas
free T3 and T4 concentrations would be inconspicuous.
Supportive for this extended model, in the study of Pan-
icker et al. as well as in ours, serum-free T4 and T3 concen-
trations did not differ between the genotype groups.
The 15q21 lead SNP, rs4338740, which was identical for
‘‘thyroid volume’’ and ‘‘goiter,’’ is located within the
second intron of FGF7 (see Figure 2). Because the minor
allele of rs4338740 is associated with increased thyroid
volume and goiter risk and the FGF7 locus is marked by
a genic lead SNP, the linked causative sequence variant
might cause an amino acid exchange in the encoded
FGF7 protein or a modified mRNA splicing site; however,The Ameneither nonsynonymous SNPs nor sequence variants pre-
dicted to influence splicing sites were identified in linkage
disequilibrium, according to the HapMap release 22 CEU
data set. Therefore, the causative sequence variation obvi-
ously has not yet been identified. FGF7 is a potent epithe-
lial-cell-specific growth factor, whose mitogenic activity is
predominantly exhibited in keratinocytes, and it is there-
fore also named keratinocyte growth factor (KGF). The
members of the fibroblast growth factor (FGF) protein
family exhibit several mitogenic and cell-survival activities
and are involved in various biological processes, including
cell growth and morphogenesis.26 The corresponding FGF
receptors are encoded by a tyrosine kinase gene family en-
compassing at least fourmembers. Themain FGF7 receptor
is the isoform IIIb of the FGF receptor 2 (FGFR2). Trans-
genic mice deficient for the murine counterpart of this
receptor (FgfR2-IIIb) exhibit, among other phenotypes,
thyroid agenesis.27 Similarly, broad midgestational expres-
sion of a kinase-deficient variant of this receptor isoform in
mice causes athyreosis.28 Hence, there are FGF signals
essential for the development of the thyroid gland. As
putative candidates, FGF1, FGF3, FGF7, and FGF10 were
already discussed.29 Indeed, FGF10 knockout mice ex-
hibited diverse phenotypes closely related to those for
FgfR2-IIIb-deficient animals, including athyreosis.30 The
FGF10 function might be related to the maintenance of
the thyroid primordium or the regulation of mitotic
activity of the thyroid gland rather than to the induction
of thyroid development.31 Therefore, it can be predicted
that the causative sequence variant underlying the
observed association causes an enhanced FGF7 signal,
thus mediating a more pronounced proliferation of
thyroid cells in risk-allele carriers, resulting in thyroid
hyperplasia and increased thyroid volume.
An open question concerned the origin of the FGF7
protein obviously influencing the thyroid volume.
The FGF protein family members involved in thyroidrican Journal of Human Genetics 88, 664–673, May 13, 2011 669
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Figure 2. Regional Association Plots Showing the Association Signals in the Regions of the Four Loci Associated with the ‘‘Thyroid
Volume’’ Phenotype on the log10 Scale as a Function of Chromosome Position in the Meta-Analysis
(A–D) The region upstream of CAPZB on chromosome 1 (A), the genic region within CAPZB on chromosome 1 (B), the FGF7 region on
chromosome 15 (C), and the ‘‘gene desert’’ on chromosome 16 (D). Large diamonds in red indicate the lead SNPs exhibiting the lowest p
values for association with the ‘‘thyroid volume’’ phenotype. The correlations (r2) between each of the surrounding SNPs and the respec-
tive lead SNP are indicated by red shading. Genes and nonsynonymous SNPs are labeled in blue. Lead SNPs that are located within genes
are indicated by red letters. The left y axis indicates the p values for the association with ‘‘thyroid volume,’’ and the right y axis indicates
the estimated recombination rates (HapMap Phase III), shown in light blue. Genes and the direction of transcription (NCBI) are dis-
played by green bars.development might be produced and secreted by the
mesenchyme surrounding the thyroid gland.29 Alterna-
tively, FGF7 could be produced by thyroid cells themselves
in an autocrine fashion. To differentiate between these
possibilities, thyroid tissue, surgically removed from ten
patients with nodular goiter, was selected from the archive
of the Institute of Pathology, University Medicine Greifs-
wald, and immunohistochemical analyses using anti-
FGF7 primary antibodies (KGF; Abcam, catalog number
ab9598) were performed. Staining was found in each
sample, strongest in leiomyocytes of arterial walls and
endothelial cells. The staining in follicle epithelial cells
was observed in each case, usually of moderate intensity
(Figure 3) but varying from negatively to strongly stained
regions. This result demonstrates that FGF7 involvement
in the modulation of thyroid volumes is present
throughout the cytoplasm of thyroid follicle epithelial
cells and therefore at least partially acts in an autocrine
manner.670 The American Journal of Human Genetics 88, 664–673, May 13,Both lead SNPs of the ‘‘gene desert’’ on 16q23 are located
directly downstream of a predicted coding sequence (gene
symbol: LOC440389), which, however, had already been
removed from the NCBI database as a result of the standard
genome annotation processing at the time that this study
was initiated. However, the predicted amino acid sequence
of the putatively encoded protein exhibits 100% identity
with a predicted Pan troglodytes protein (encoded by
LOC454261). Furthermore, the local genomic context of
this region is comparable between both species: the
distance between MAF and LOC440389 in Homo sapiens
and the distance between MAF and LOC454261 in Pan
troglodytes both amount to 121 kb, and in both species,
both genes are transcribed in the same direction. The two
lead SNPs are located within a region of elevated linkage
disequilibrium that encompasses the furthermost 30- end
of the putative gene and the region immediately down-
stream of it. Therefore, we hypothesized that the putative
causative sequence variant(s) affecting the thyroid size2011
Figure 3. Immunohistochemical Detection of FGF7
Immunohistochemical detection of FGF7 in thyroid follicle
epithelial cells (arrows). Colloid within the follicles is unstained
(asterisks). Endothelial cells also react positively (dotted arrows).
The lower edge of the panel measures 250 mm.
Figure 4. Northern Analysis Demonstrating the Presence of an
LOC440389-Specific mRNA of around 0.8 kb in Skeletal Muscle
Tissue and Thyroid Tissue
SM, skeletal muscle tissue; Thy, thyroid tissue. The first two lanes
(SM and Thy) contained 5 mg of total tissue-specific RNA each. The
right lane (MW) represents the RNA molecular weight standard.
Total RNA was separated by electrophoresis in a 1.2% gel, and,
after blotting, the nylon membrane was hybridized with
a LOC440389-specific RNA probe.might influence the LOC440389 expression via modula-
tion of its 30- trailer sequence. Indeed, it is known that
30- untranslated regions (30- UTRs) of human protein-
coding genes are rich in miRNA target sites, and it has
been proposed that miRNA regulation may be affected by
polymorphisms in 30-UTRs. 32
Because these considerations were based on the assump-
tion that LOC440389 indeed represents a ‘‘real’’ gene, an
experiment aimed at detecting a specific, mature
LOC440389 mRNA was designed. Because the LOC440389
locus influences the thyroid volume, it was speculated that
expression of the postulated gene occurs with increased
likelihood in thyroid tissue. Therefore, a tissue-specific
cDNA library was generated by reverse transcription of
human thyroid total RNA (Ambion). This library served
as a template in a PCR reaction using a primer pair
designed for amplification of the predicted cDNA
derived from the postulated LOC440389 mRNA (see
Supplemental Material and Methods). The complete
amplified LOC440389 coding region spanning all four
exon-intron boundaries was calculated to encompass 258
base pairs. Given that the 30-primer was extended by
a tail containing a T7 promoter sequence, the total size
of the PCR product should amount to 282 base pairs.
Indeed, a specific PCR product of the predicted size was
obtained. Sequencing of both strands of this PCR product
(LGC Genomics) proved that the cDNA sequence exactly
corresponded to the published LOC440389 mRNA
sequence (see Supplemental Material and Methods) ex-
pected from the database entry (XM_498648.3). This
clearly demonstrated that LOC440389 indeed represents
a real gene and that the withdrawal of its annotation
from the NCBI database was incorrect. Furthermore,
tissue-specific expression of this gene in the thyroid was
proven. To determine the size of the LOC440389 tran-The Amescript, we performed an RNA hybridization analysis using
a digoxigenin-labeled RNA probe complementary to the
complete predicted LOC440389 mRNA and total RNA
prepared from thyroid tissue and, as a control, from
skeletal muscle, as described previously.33 The cheminolu-
minescence signals obtained clearly demonstrated the
presence of a distinct mRNA in the predicted size range
of 700 nucleotides (Figure 4). Densitometrical analysis of
the bands revealed that the transcript was threefold more
abundant in thyroid than in skeletal muscle. Additional
analyses are necessary for determining the physiological
function of the protein encoded by LOC440389, especially
in the context of its relationship to thyroid volume. The
finding of a stronger expression of the gene in thyroid
tissue than in skeletal muscle tissue might serve as a first
hint of a thyroid-specific function of the protein.
Finally, it has to be emphasized that iodine supply of
a population represents the major environmental risk
factor for goiter. Given that both populations investigated
herein were recruited from areas with highly comparable
iodine supply, the present results are representative for
formerly and, probably, currently iodine-deficient regions.
The representativeness of our findings for iodine-replete
regions, however, has to be investigated.Supplemental Data
Supplemental Data include Supplemental Material and Methods,
one table, and two figures and can be foundwith this article online
at http://www.cell.com/AJHG/.Acknowledgments
SHIP is part of the CommunityMedicine Research net of the Ernst-
Moritz-Arndt-University Greifswald, Germany, which is funded by
the Federal Ministry of Education and Research, the Ministry of
Cultural Affairs, and the Social Ministry of the Federal State of
Mecklenburg-West Pomerania. Genome-wide data have been
supported by the Federal Ministry of Education and Research
(grant no. 03ZIK012) and a joint grant from Siemens Healthcare
(Erlangen, Germany) and the Federal State of Mecklenburg-West
Pomerania. The SHIP authors are grateful to the contribution of
Anja Wiechert and Astrid Petersmann in generating the SNPrican Journal of Human Genetics 88, 664–673, May 13, 2011 671
data and to Marc Schaffer for his assistance in the RNA analysis.
The University of Greifswald is a member of the ‘‘Center of Knowl-
edge Interchange’’ program of Siemens AG. Data analyses were
further supported by the German Research Foundation (DFG Vo
955/10-1) and the Federal Ministry of Nutrition, Agriculture and
Comsumer’s Safety.
The KORA research platform was initiated and financed by the
Helmholtz Center Munich, by the German Research Center for
Environmental Health, which is funded by the German Federal
Ministry of Education and Research, and by the State of Bavaria.
The work of KORA is supported by the German Federal Ministry
of Education and Research (BMBF) in the context of the German
National Genome Research Network (NGFN-2 and NGFN-plus).
Our research was supported within the Munich Center of Health
Sciences (MC Health) as part of LMUinnovativ. Thyroid examina-
tions were funded by Sanofi-Aventis within the framework of the
Papillon Initiative.
Received: December 23, 2010
Revised: March 28, 2011
Accepted: April 21, 2011
Published online: May 12, 2011Web Resources
The URLs for data presented herein are as follows:
HapMap, http://www.hapmap.org
IMPUTE software, http://www.stats.ox.ac.uk/~marchini/software/
gwas/impute
METAL package, http://www.sph.umich.edu/csg/abecasis/metal
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
QUICKTEST, http://toby.freeshell.org/software/quicktest.shtml
R 2.4.1, http://www.R-project.org
SNAP, http://www.broadinstitute.org/mpg/snap/
SNPTEST, http://www.stats.ox.ac.uk/~marchini/software/gwas/
snptest.html
UCSC Genome Browser, http://genome.ucsc.eduReferences
1. Laurberg, P., Pedersen, K.M., Hreidarsson, A., Sigfusson, N.,
Iversen, E., and Knudsen, P.R. (1998). Iodine intake and the
pattern of thyroid disorders: a comparative epidemiological
study of thyroid abnormalities in the elderly in Iceland and
in Jutland, Denmark. J. Clin. Endocrinol. Metab. 83, 765–769.
2. Teng, W., Shan, Z., Teng, X., Guan, H., Li, Y., Teng, D., Jin, Y.,
Yu, X., Fan, C., Chong,W., et al. (2006). Effect of iodine intake
on thyroid diseases in China. N. Engl. J. Med. 354, 2783–2793.
3. Vo¨lzke, H., Schwahn, C., Kohlmann, T., Kramer, A., Robinson,
D.M., John, U., and Meng, W. (2005). Risk factors for goiter in
a previously iodine-deficient region. Exp. Clin. Endocrinol.
Diabetes 113, 507–515.
4. Ittermann, T., Schmidt, C.O., Kramer, A., Below, H., John, U.,
Thamm, M., Wallaschofski, H., and Vo¨lzke, H. (2008).
Smoking as a risk factor for thyroid volume progression and
incident goiter in a region with improved iodine supply. Eur.
J. Endocrinol. 159, 761–766.
5. Knudsen, N., Laurberg, P., Perrild, H., Bu¨low, I., Ovesen, L.,
and Jørgensen, T. (2002). Risk factors for goiter and thyroid
nodules. Thyroid 12, 879–888.672 The American Journal of Human Genetics 88, 664–673, May 13,6. Brix, T.H., Kyvik, K.O., and Hegedu¨s, L. (1999). Major role of
genes in the etiology of simple goiter in females: a population-
based twin study. J. Clin. Endocrinol. Metab. 84, 3071–3075.
7. Hansen, P.S., Brix, T.H., Bennedbaek, F.N., Bonnema, S.J.,
Kyvik, K.O., and Hegedu¨s, L. (2004). Genetic and environ-
mental causes of individual differences in thyroid size: a study
of healthy Danish twins. J. Clin. Endocrinol. Metab. 89, 2071–
2077.
8. Meng, W., Schindler, A., Horack, S., Lux, E., and Muche, A.
(1998). Renal iodine excretion by students in East Germany.
A prospective study 1989 to 1996. Med. Klin. (Munich) 93,
347–351.
9. Meng, W.S.A. (1998). Iodine Supply in Germany. In Elimina-
tion of Iodine Deficiency Disorders (IDD) in Central and
Eastern Europe, the Commonwealth of Independent States
and the Baltic States, F. Delange, A. Robertson, E. McLough-
ney, and G. Gerasimov, eds. (Munich, Germany:World Health
Organization), pp. 21–27.
10. Volzke, H., Alte, D., Schmidt, C.O., Radke, D., Lorbeer, R., Frie-
drich, N., Aumann, N., Lau, K., Piontek, M., Born, G., et al.
(2010). Cohort Profile: The Study of Health in Pomerania.
Int. J. Epidemiol. 40, 294–307.
11. Wichmann, H.E., Gieger, C., and Illig, T.; MONICA/KORA
Study Group. (2005). KORA-gen—resource for population
genetics, controls and a broad spectrum of disease pheno-
types. Gesundheitswesen 67 (Suppl 1 ), S26–S30.
12. Gutekunst, R., Becker, W., Hehrmann, R., Olbricht, T., and
Pfannenstiel, P. (1988). Ultrasonic diagnosis of the thyroid
gland. Dtsch. Med. Wochenschr. 113, 1109–1112.
13. Brix, T.H., Kyvik, K.O., and Hegedu¨s, L. (2001). Validity of self-
reported hyperthyroidism and hypothyroidism: comparison
of self-reported questionnaire data with medical record
review. Thyroid 11, 769–773.
14. Bergmann, M.M., Jacobs, E.J., Hoffmann, K., and Boeing, H.
(2004). Agreement of self-reported medical history: compar-
ison of an in-person interview with a self-administered
questionnaire. Eur. J. Epidemiol. 19, 411–416.
15. Soranzo, N., Spector, T.D., Mangino, M., Ku¨hnel, B., Rendon,
A., Teumer, A., Willenborg, C., Wright, B., Chen, L., Li, M.,
et al. (2009). A genome-wide meta-analysis identifies 22 loci
associated with eight hematological parameters in the Haem-
Gen consortium. Nat. Genet. 41, 1182–1190.
16. Pe’er, I., Yelensky, R., Altshuler, D., and Daly, M.J. (2008).
Estimation of the multiple testing burden for genomewide
association studies of nearly all common variants. Genet.
Epidemiol. 32, 381–385.
17. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira,
M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly,
M.J., and Sham, P.C. (2007). PLINK: a tool set for whole-
genome association and population-based linkage analyses.
Am. J. Hum. Genet. 81, 559–575.
18. Schafer, D.A., Korshunova, Y.O., Schroer, T.A., and Cooper,
J.A. (1994). Differential localization and sequence analysis of
capping protein beta-subunit isoforms of vertebrates. J. Cell
Biol. 127, 453–465.
19. Schafer, D.A., Jennings, P.B., and Cooper, J.A. (1996).
Dynamics of capping protein and actin assembly in vitro: un-
capping barbed ends by polyphosphoinositides. J. Cell Biol.
135, 169–179.
20. Yamashita, A., Maeda, K., and Mae´da, Y. (2003). Crystal struc-
ture of CapZ: structural basis for actin filament barbed end
capping. EMBO J. 22, 1529–1538.2011
21. Mejillano, M.R., Kojima, S., Applewhite, D.A., Gertler, F.B.,
Svitkina, T.M., and Borisy, G.G. (2004). Lamellipodial versus
filopodial mode of the actin nanomachinery: pivotal role of
the filament barbed end. Cell 118, 363–373.
22. Cooper, J.A., and Sept, D. (2008). New insights into mecha-
nism and regulation of actin capping protein. Int. Rev. Cell
Mol. Biol. 267, 183–206.
23. Kitazawa, M., Yamakuni, T., Song, S.Y., Kato, C., Tsuchiya, R.,
Ishida, M., Suzuki, N., Adachi, E., Iwashita, S., Ueno, S., et al.
(2005). Intracellular cAMP controls a physical association of
V-1 with CapZ in cultured mammalian endocrine cells.
Biochem. Biophys. Res. Commun. 331, 181–186.
24. Amatruda, J.F., Gattermeir, D.J., Karpova, T.S., and
Cooper, J.A. (1992). Effects of null mutations and overex-
pression of capping protein on morphogenesis, actin distri-
bution and polarized secretion in yeast. J. Cell Biol. 119,
1151–1162.
25. Panicker, V., Wilson, S.G., Walsh, J.P., Richards, J.B., Brown,
S.J., Beilby, J.P., Bremner, A.P., Surdulescu, G.L., Qweitin, E.,
Gillham-Nasenya, I., et al. (2010). A locus on chromosome
1p36 is associated with thyrotropin and thyroid function as
identified by genome-wide association study. Am. J. Hum.
Genet. 87, 430–435.
26. Ornitz, D.M., and Itoh, N. (2001). Fibroblast growth factors.
Genome Biol. 2, REVIEWS3005.
27. Revest, J.M., Spencer-Dene, B., Kerr, K., De Moerlooze, L.,
Rosewell, I., and Dickson, C. (2001). Fibroblast growth factor
receptor 2-IIIb acts upstream of Shh and Fgf4 and is required
for limb bud maintenance but not for the induction of Fgf8,
Fgf10, Msx1, or Bmp4. Dev. Biol. 231, 47–62.The Ame28. Celli, G., LaRochelle, W.J., Mackem, S., Sharp, R., andMerlino,
G. (1998). Soluble dominant-negative receptor uncovers
essential roles for fibroblast growth factors in multi-organ
induction and patterning. EMBO J. 17, 1642–1655.
29. DeMoerlooze, L., Spencer-Dene, B., Revest, J.M., Hajihosseini,
M., Rosewell, I., and Dickson, C. (2000). An important role for
the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2)
in mesenchymal-epithelial signalling during mouse organo-
genesis. Development 127, 483–492.
30. Ohuchi, H., Hori, Y., Yamasaki, M., Harada, H., Sekine, K.,
Kato, S., and Itoh, N. (2000). FGF10 acts as a major ligand
for FGF receptor 2 IIIb in mouse multi-organ development. Bi-
ochem. Biophys. Res. Commun. 277, 643–649.
31. De Felice, M., and Di Lauro, R. (2004). Thyroid development
and its disorders: genetics and molecular mechanisms. En-
docr. Rev. 25, 722–746.
32. Landi, D., Gemignani, F., Naccarati, A., Pardini, B., Vodicka, P.,
Vodickova, L., Novotny, J., Fo¨rsti, A., Hemminki, K., Canzian,
F., and Landi, S. (2008). Polymorphisms within micro-RNA-
binding sites and risk of sporadic colorectal cancer. Carcino-
genesis 29, 579–584.
33. Homuth, G., Masuda, S., Mogk, A., Kobayashi, Y., and Schu-
mann, W. (1997). The dnaK operon of Bacillus subtilis is hep-
tacistronic. J. Bacteriol. 179, 1153–1164.
34. Brunn, J., Block, U., Ruf, G., Bos, I., Kunze, W.P., and Scriba,
P.C. (1981). Volumetric analysis of thyroid lobes by real-time
ultrasound (author’s transl). Dtsch. Med. Wochenschr. 106,
1338–1340.
35. Bland, J.M., and Altman, D.J. (1986). Regression analysis.
Lancet 1, 908–909.rican Journal of Human Genetics 88, 664–673, May 13, 2011 673
